

# WFS1 R832G — Wolframin

Arginine → Glycine at position 832. C-terminal ER-lumenal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.691, DynaMut2  $\Delta\Delta G$  -0.46 kcal/mol (destabilising).

## IDENTITY

Variant	R832G (p.Arginine832Glycine)
DNA change	c.2494C>G
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV003718609
Amino acid change	Arginine (R) → Glycine (G)

## STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 832	<b>81.00</b> HIGH CONFIDENCE
Domain	C-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position context	C-terminal lumenal domain · position 832 projects into the ER lumen
IDR flag	No — pLDDT well above 50 threshold

Position 832 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na<sup>+</sup>/K<sup>+</sup> ATPase  $\beta$ 1. The wild-type residue is positively charged (arginine — guanidinium, strong H-bond donor); the mutant is small/flexible (glycine — backbone flexibility, no sidechain). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

## COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

**0.691**am\_class: **likely pathogenic** —  
threshold > 0.564DYNAMUT2  $\Delta\Delta G$ **-0.46** kcal/molDestabilising · Job  
178092126343

PLDDT (ALPHAFOLD)

**81.00**

high confidence

## CLINICAL EVIDENCE

ClinVar classification	UNCERTAIN SIGNIFICANCE
Review status	criteria provided, single submitter
Last evaluated	2024/04/07 00:00
Inheritance	Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscape	R832G is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar) <ul style="list-style-type: none"><li>(no conditions catalogued)</li></ul>

## RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$  + binding site affected → CATEGORY 3 – docking experiments  $\Delta\Delta G 2-4$  → CATEGORY 2 – pharmacological chaperones  $\Delta\Delta G > 4$  → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

### Category 3/4 — Most Druggable

$|\Delta\Delta G|=0.46 < 2$  kcal/mol (fold intact) + AlphaMissense 0.691 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Wolframín's fold survives this substitution ( $|\Delta\Delta G|=0.46$  kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.691. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.